| OSX focuses on Ortho line in Singapore via direct selling | Nov 1, 2026 | Operations update | ASX |
|---|
| Activities Report September 2026 and Appendix 4C | Oct 30, 2026 | Quarterly report | ASX |
|---|
| Resignation and appointment of Company Secretary | Oct 2, 2026 | Management or board change | ASX |
|---|
| OSX secures market access to Thailand orthopaedic market | Sep 8, 2026 | Operations update | ASX |
|---|
| Half Yearly Report and Accounts | Aug 31, 2026 | Interim report | ASX |
|---|
| OSX strikes orthopaedic deal for 5 Middle East countries | Aug 5, 2026 | Acquisition or disposal | ASX |
|---|
| Details of Auditor Appointment/Resignation | Aug 3, 2026 | Other filings | ASX |
|---|
| OSX completes first Hainan custom orthopaedic implant | Aug 2, 2026 | Operations update | ASX |
|---|
| Activities Report June 2026 and Appendix 4C | Jul 30, 2026 | Quarterly report | ASX |
|---|
| OSX secures Hainan FDA approval for orthopaedic devices | May 25, 2026 | Operations update | ASX |
|---|
| Activities Report March 2026 and Appendix 4C | Apr 29, 2026 | Quarterly report | ASX |
|---|
| Further Drawdown of T2 of the Redeemable Convertible Notes | Mar 26, 2026 | Financing | ASX |
|---|
| Clarification - agreement for injectable regen bone filler | Mar 12, 2026 | Operations update | ASX |
|---|
| OSX signs agreement for injectable regenerative bone filler | Mar 11, 2026 | Operations update | ASX |
|---|
| OSX secures distribution for autologous dentin bone graft | Mar 2, 2026 | Operations update | ASX |
|---|
| Appendix 4E Preliminary Final Report | Feb 27, 2026 | Annual report | ASX |
|---|
| Drawdown of Tranche 2 of the Redeemable Convertible Notes | Feb 16, 2026 | Financing | ASX |
|---|
| OSX secures Latin America deal for craniofacial distribution | Feb 12, 2026 | Operations update | ASX |
|---|
| Further Drawdown of T1 of the Redeemable Convertible Notes | Feb 6, 2026 | Financing | ASX |
|---|
| Activities Report December 2025 and Appendix 4C | Jan 29, 2026 | Quarterly report | ASX |
|---|
| Clarification - agreement for orthopaedic products in HK | Jan 22, 2026 | Other filings | ASX |
|---|
| OSX strikes agreement for orthopaedic products in Hong Kong | Jan 21, 2026 | Operations update | ASX |
|---|
| Clarification - OSX partner Chinese dental & maxillofacial | Jan 16, 2026 | Operations update | ASX |
|---|
| OSX partners up for Chinese dental & maxillofacial market | Jan 15, 2026 | Acquisition or disposal | ASX |
|---|
| OSX partners DKSH for dental products in Malaysia | Nov 24, 2025 | Operations update | ASX |
|---|
| Activities Report September 2025 and Appendix 4C | Oct 30, 2025 | Quarterly report | ASX |
|---|
| OSX collaborates with TTSH to develop novel implant for AVN | Sep 8, 2025 | Operations update | ASX |
|---|
| OSX Invests AUD 0.5m in Cellular Regenerative Medicine | Aug 31, 2025 | Operations update | ASX |
|---|
| Half Yearly Report and Accounts | Aug 29, 2025 | Interim report | ASX |
|---|
| OSX ortho product successful in Vietnam hospital tender bids | Aug 3, 2025 | Operations update | ASX |
|---|
| Activities Report June 2025 and Appendix 4C | Jul 30, 2025 | Quarterly report | ASX |
|---|
| Business progress update, Zimmer Biomet sales units grows 3x | Jul 28, 2025 | Operations update | ASX |
|---|
| Osteopore gains access to Switzerland | Jul 13, 2025 | Operations update | ASX |
|---|
| Activities Report March 2025 and Appendix 4C | Apr 28, 2025 | Quarterly report | ASX |
|---|
| Osteopore secures EU market approvals for custom implants | Apr 8, 2025 | Operations update | ASX |
|---|
| Reinstatement to Quotation | Apr 7, 2025 | Trading halt or suspension | ASX |
|---|
| Suspension from Quotation | Mar 31, 2025 | Trading halt or suspension | ASX |
|---|
| Convertible Note Prospectus | Mar 28, 2025 | Financing | ASX |
|---|
| Drawdown of Tranche 1 of the Redeemable Convertible Notes | Feb 14, 2025 | Financing | ASX |
|---|
| Activities Report December 2024 and Appendix 4C | Jan 30, 2025 | Quarterly report | ASX |
|---|
| OSX enters agreement to issue redeemable convertible notes | Dec 24, 2024 | Financing | ASX |
|---|
| OSX partners scientists to drive regeneration innovation | Nov 3, 2024 | Operations update | ASX |
|---|
| Activities Report September 2024 and Appendix 4C | Oct 30, 2024 | Quarterly report | ASX |
|---|
| Osteopore to raise A$20m via redeemable convertible note | Sep 26, 2024 | Financing | ASX |
|---|
| OSX and University of Chile complete bone implant studies | Aug 21, 2024 | Operations update | ASX |
|---|
| Activities Update Qtr Ending June 2024 and Appendix 4C | Jul 30, 2024 | Quarterly report | ASX |
|---|
| Osteopore strikes Exclusive Distribution with Zimmer Biomet | Jul 15, 2024 | Other filings | ASX |
|---|
| A$18.7m Osteopore, NDCS and A*STAR project hits milestones | Jun 5, 2024 | Operations update | ASX |
|---|
| OSX and SingHealth partner on Global Centre of Excellence | May 13, 2024 | Operations update | ASX |
|---|
| Osteopore successfully raises A$2.9m from Entitlement Offer | May 7, 2024 | Financing | ASX |
|---|
| Activities Update Qtr Ending March 2024 and Appendix 4C | Apr 29, 2024 | Quarterly report | ASX |
|---|
| Response to ASX Price and Volume Query | Apr 23, 2024 | Explanation request | ASX |
|---|
| Trading Halt | Apr 23, 2024 | Trading halt or suspension | ASX |
|---|
| Pause in Trading | Apr 23, 2024 | Trading halt or suspension | ASX |
|---|
| Reinstatement to Official Quotation | Apr 16, 2024 | Trading halt or suspension | ASX |
|---|
| Response to ASX Query Letter | Apr 15, 2024 | Explanation request | ASX |
|---|
| Osteopore extends Bridging Loan maturity date | Apr 10, 2024 | Financing | ASX |
|---|
| Replacement Prospectus for Renounceable Rights Issue | Apr 4, 2024 | Offer document | ASX |
|---|
| Update to Replacement Prospectus for Entitlement Offer | Apr 3, 2024 | Offer document | ASX |
|---|
| Osteopore secures Singapore and Vietnam market approvals | Mar 26, 2024 | Operations update | ASX |
|---|
| Prospectus for Renounceable Rights Issue | Mar 12, 2024 | Offer document | ASX |
|---|
| OSX Entitlement Offer to support growth | Mar 12, 2024 | Financing | ASX |
|---|
| Activities Update Qtr Ending December 2023 and Appendix 4C | Jan 30, 2024 | Quarterly report | ASX |
|---|
| Notice of General Meeting | Jan 23, 2024 | Meeting notice | ASX |
|---|
| Osteopore signs Bridging Loan agreement | Dec 28, 2023 | Financing | ASX |
|---|
| Activities Update Qtr Ending September 2023 and Appendix 4C | Oct 30, 2023 | Quarterly report | ASX |
|---|
| MOU with Temasek-linked Innoventures - Orthopaedics in China | Sep 11, 2023 | Other filings | ASX |
|---|
| Activities Update Qtr Ending June 2023 and Appendix 4C | Jul 30, 2023 | Quarterly report | ASX |
|---|
| OSX receives A$10m commitment for commercialisation in China | Jul 24, 2023 | Other filings | ASX |
|---|
| Osteopore strengthens Board & Management by key appointments | Jul 17, 2023 | Other filings | ASX |
|---|
| Strategic Partnership for Clinical R&D in China worth $4M | Jun 7, 2023 | Other filings | ASX |
|---|
| Largest South African Medical Insurer provides cover for OSX | May 15, 2023 | Other filings | ASX |
|---|
| Activities Update Qtr Ending March 2023 and Appendix 4C | Apr 27, 2023 | Quarterly report | ASX |
|---|
| OSX Successfully transitions to EU Medical Device Regulation | Apr 26, 2023 | Other filings | ASX |
|---|
| Reinstatement of Security Class to Quotation | Apr 25, 2023 | Other filings | ASX |
|---|
| Security Class Suspension from Quotation | Apr 24, 2023 | Trading halt or suspension | ASX |
|---|
| Non-Renounceable Entitlement Offer - Results | Apr 24, 2023 | Financing | ASX |
|---|
| OSX Strengthens Presence in the Eastern Region of the USA | Apr 10, 2023 | Other filings | ASX |
|---|
| OSX Completes Acquisition to Accelerate Revenue Growth | Mar 30, 2023 | Acquisition or disposal | ASX |
|---|
| Non-Renounceable Entitlement Offer Prospectus | Mar 12, 2023 | Financing | ASX |
|---|
| Non-Renounceable Entitlement Offer | Mar 12, 2023 | Financing | ASX |
|---|
| Activities Update Qtr Ending December 2022 and Appendix 4C | Jan 30, 2023 | Quarterly report | ASX |
|---|
| Integration of Acquired Business for Higher Sales & Margin | Jan 22, 2023 | Acquisition or disposal | ASX |
|---|
| Firm Commitments and Non-Binding Proposed Acquisition | Dec 21, 2022 | Acquisition or disposal | ASX |
|---|
| Suspension from Official Quotation | Dec 20, 2022 | Trading halt or suspension | ASX |
|---|
| Increased presence and commercial opportunities across SEA | Dec 7, 2022 | Other filings | ASX |
|---|
| Activities Update Qtr Ending September 2022 and Appendix 4C | Oct 30, 2022 | Quarterly report | ASX |
|---|
| Osteopore Moves Closer to China Market Entry | Aug 22, 2022 | Other filings | ASX |
|---|
| Activities Update Qtr Ending June 2022 and Appendix 4C | Jul 25, 2022 | Quarterly report | ASX |
|---|
| OSX Enter Oral & Maxillofacial Market in Australia & NZ | May 10, 2022 | Other filings | ASX |
|---|
| Activities Update Qtr Ending March 2022 and Appendix 4C | Apr 28, 2022 | Quarterly report | ASX |
|---|
| SHG: & CSIRO AI Tool to Optimise Cranial Implant Procedures | Mar 13, 2022 | Other filings | ASX |
|---|
| Activities Update Qtr Ending December 2021 and Appendix 4C | Jan 27, 2022 | Quarterly report | ASX |
|---|
| Osteopore secures A$19m clinical-industrial partnership | Dec 13, 2021 | Other filings | ASX |
|---|
| Activities Update Qtr Ending September 2021 and Appendix 4C | Oct 29, 2021 | Quarterly report | ASX |
|---|
| SHG: CSIRO Collaboration for AI-based Tool | Oct 18, 2021 | Other filings | ASX |
|---|
| Activities Update Qtr Ending June 2021 and Appendix 4C | Jul 30, 2021 | Quarterly report | ASX |
|---|
| Activities Update Qtr Ending March 2021 and Appendix 4C | Apr 30, 2021 | Quarterly report | ASX |
|---|
| Agreement with Terumo Blood and Cell Technologies | Jan 31, 2021 | Other filings | ASX |
|---|
| Activities Update Qtr Ending December 2020 and Appendix 4C | Jan 29, 2021 | Quarterly report | ASX |
|---|
| OSX Signs Australian & New Zealand Distribution Agreement | Oct 30, 2020 | Other filings | ASX |
|---|
| Activities Update Qtr Ending September 2020 and Appendix 4C | Oct 29, 2020 | Quarterly report | ASX |
|---|
| Investor Presentation | Aug 21, 2020 | Other filings | ASX |
|---|
| Osteopore Receives Binding Commitments for $8.5m Placement | Aug 20, 2020 | Financing | ASX |
|---|
| Activities Update Quarter Ending June 2020 and Appendix 4C | Jul 31, 2020 | Quarterly report | ASX |
|---|
| Development of New 3D Printed Bone Implant | Jul 22, 2020 | Other filings | ASX |
|---|
| Clarification on Initial US Distribution Agreement | Jul 2, 2020 | Other filings | ASX |
|---|
| Osteopore Signs Initial U.S. Distribution Agreement | Jul 1, 2020 | Other filings | ASX |
|---|
| Activities Update Quarter Ending March 2020 and Appendix 4C | Apr 30, 2020 | Quarterly report | ASX |
|---|
| Osteopore Receives Australian TGA Approval | Apr 19, 2020 | Other filings | ASX |
|---|
| Pause In Trading | Apr 16, 2020 | Trading halt or suspension | ASX |
|---|
| Company Update | Apr 8, 2020 | Other filings | ASX |
|---|
| Company Update and Appendix 4C | Jan 30, 2020 | Quarterly report | ASX |
|---|
| Former President and CEO of Cochlear Joins as Board Advisor | Dec 3, 2019 | Other filings | ASX |
|---|
| OSX Executes Memorandum of Co-operation in Hainan Province | Nov 18, 2019 | Other filings | ASX |
|---|